ArticleCancer chemotherapy and pharmacology2012

Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.

David A Reardon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.